iShares Genomics Immunology and Healthcare Idx ETF (XDNA.TO)
37.56
+0.13
(+0.35%)
CAD |
TSX |
Dec 15, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.44% | 0.13% | 5.622M | 303.30 |
| Weighted Average Dividend Yield | Turnover Ratio (Generic) | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.64% | 58.20% | 0.00 | Upgrade |
Basic Info
| Investment Strategy | |
| XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. Under normal market conditions, XDNA will primarily invest in securities of one or more iShares ETFs and/or international equity securities. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health Care Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | BlackRock |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 16, 2025.
Asset Allocation
As of November 30, 2025.
| Type | % Net |
|---|---|
| Cash | 0.26% |
| Stock | 99.74% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Basic Info
| Investment Strategy | |
| XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. Under normal market conditions, XDNA will primarily invest in securities of one or more iShares ETFs and/or international equity securities. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health Care Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | BlackRock |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |